Patents by Inventor Marc Blouin

Marc Blouin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tri-aryl ethane derivatives as PDE IV inhibitors
    Patent number: 5710170
    Abstract: The invention encompasses the novel compound of Formula I useful in the treatment of diseases, including asthma, by raising the level of cyclic adenosine-3',5'-monophosphate (cAMP) through the inhibition of phosphodiesterase IV (PDE IV). ##STR1## The invention also encompasses certain pharmaceutical compositions and methods for treatment of diseases by inhibition of PDE IV, resulting in an elevation of cAMP, comprising the use of compounds of Formula I.
    Type: Grant
    Filed: December 10, 1996
    Date of Patent: January 20, 1998
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Daniel Guay, Yves Girard, Yves Ducharme, Marc Blouin, Pierre Hamel, Mario Girard
  • Heteroaryl quinolines as inhibitors of leukotriene biosynthesis
    Patent number: 5410054
    Abstract: Compounds having the formula I: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection and in preventing the formation of atherosclerotic plaques.
    Type: Grant
    Filed: July 20, 1993
    Date of Patent: April 25, 1995
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Rick Friesen, Robert N. Young, Yves Girard, Marc Blouin, Daniel Dube
  • Indole carbamates as leukotriene antagonists
    Patent number: 5334597
    Abstract: Compounds having the formula I: ##STR1## are antagonists of the actions of leukotrienes. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection.
    Type: Grant
    Filed: October 17, 1991
    Date of Patent: August 2, 1994
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Petpiboon Prasit, Marc Blouin